Pharmaceutical composition of substituted 2-(pyrrolidin-3-yl)acetic acid derivative and use thereof

By preparing a pharmaceutical composition containing a substituted 2-(pyrrolidine-3-yl)acetic acid derivative, the problem of the lack of effective methods to reduce lipoprotein(a) plasma levels in the prior art is solved, providing a treatment option for cardiovascular diseases and improving patient compliance.

WO2026238030A1PCT designated stage Publication Date: 2026-11-19INNOVSTONE THERAPEUTICS LIMITED
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
PCT/CN2026/096878
Authority / Receiving Office
WO · WO
Patent Type
Applications
Current Assignee / Owner
Priority Date
2025-05-15
Filing Date
2026-05-14
Publication Date
2026-11-19

AI Technical Summary

Technical Problem

Currently, there is a lack of effective drug therapies to lower plasma lipoprotein(a) levels, and existing treatment options are limited and have poor adherence, which increases the risk of cardiovascular disease.

Method used

A pharmaceutical composition comprising a substituted 2-(pyrrolidone-3-yl)acetic acid derivative is provided, which, by preparing different dosage forms and formulations and combining with appropriate excipients, is formulated into a solid oral dosage form such as a tablet for lowering plasma levels of lipoprotein(a).

Benefits of technology

It has achieved an effective reduction in lipoprotein(a) levels, providing treatment options for cardiovascular diseases and improving patient compliance.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure PCTCN2026096878-FTAPPB-I100001
    Figure PCTCN2026096878-FTAPPB-I100001
  • Figure PCTCN2026096878-FTAPPB-I100002
    Figure PCTCN2026096878-FTAPPB-I100002
  • Figure PCTCN2026096878-FTAPPB-I100003
    Figure PCTCN2026096878-FTAPPB-I100003
Patent Text Reader

Abstract

The present invention provides a compound as an Lp(a) inhibitor, particularly a pharmaceutical composition of a substituted 2-(pyrrolidin-3-yl)acetic acid derivative, a preparation method therefor, and use thereof.
Need to check novelty before this filing date? Find Prior Art

Description

Pharmaceutical compositions of substituted 2-(pyrrolidine-3-yl)acetic acid derivatives and their applications Technical Field

[0001] This invention relates to the field of pharmaceutical formulation technology, and more particularly, to pharmaceutical compositions comprising compounds as Lp(a) inhibitors, especially substituted 2-(pyrrolidone-3-yl)acetic acid derivatives, methods of preparation thereof, and applications thereof. Background Technology

[0002] Lipoprotein(a) (Lp(a)) are lipoprotein particles synthesized in the liver, consisting of cholesterol-rich low-density lipoprotein (LDL-C)-like particles attached to apolipoprotein(a). Lp(a) levels are primarily determined by genes, vary significantly among different populations, and are almost unaffected by lifestyle interventions.

[0003] Lp(a) is associated with an increased risk of coronary artery disease, ischemic stroke, aortic stenosis, heart failure, atrial fibrillation, and peripheral artery disease. Approximately 20% of the population has elevated serum Lp(a) levels (≥30 mg / dL). The increased risk of cardiovascular disease (CVD) associated with Lp(a) is primarily attributed to the dual procoagulant effect of Apo(a) (Apo(a) has a structure similar to plasminogen), and the atherogenic (AS) and pro-inflammatory effects of Apo B (apolipoprotein B) containing oxidized phospholipid components (OxPL). Lp(a) is a contributing factor not only to atherosclerotic cardiovascular disease (ASCVD) but also to calcific aortic valve disease. Elevated plasma Lp(a) levels are an independent risk factor for CVD.

[0004] For patients with elevated Lp(a) levels, approved treatment options are limited. Apheresis can be used to filter blood to remove LDL and Lp(a); however, the effects are temporary and usually require repetition every two weeks, and patient adherence is not good. Currently, there are no approved drug therapies for lowering Lp(a) levels. Therefore, it is essential to provide patients with CVD with pharmaceutically acceptable compounds and treatment options to lower plasma Lp(a) levels. Summary of the Invention

[0005] In a first aspect, the present invention provides a pharmaceutical composition comprising: a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient and an excipient, said composition being formulated in a single-dose form, wherein the single-dose form comprises 0.001 mg to 3000 mg of compound (I).

[0006] In some embodiments, the single-dose form comprises 0.001 mg to 2000 mg of compound (I); preferably 0.1 mg to 1800 mg of compound (I); more preferably 0.1 mg to 1500 mg of compound (I); more preferably 0.1 mg to 1000 mg of compound (I); more preferably 0.1 mg to 800 mg of compound (I); more preferably 1 mg to 500 mg of compound (I); more preferably 1 mg to 200 mg of compound (I); more preferably 1 mg to 100 mg of compound (I); more preferably 5 mg to 500 mg of compound (I); more preferably 10 mg to 500 mg of compound (I); more preferably 10 mg to 200 mg of compound (I); more preferably 10 mg to 100 mg of compound (I). For example, the content of a single-dose pharmaceutical composition of the compound of formula (I) or a pharmaceutically acceptable salt thereof may be 0.1 mg, 0.2 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 120 mg, 125 mg, etc. mg, 140mg, 150mg, 160mg, 170mg, 175mg, 180mg, 200mg, 220mg, 240mg, 250mg, 260mg, 280mg, 300mg, 350mg, 400mg, 450mg, 500mg, 600mg, 700mg, 800mg, 900mg, 1000mg, 1200mg, 1400mg, 1500mg, 1600mg, 1800mg, 2000mg, 2500mg, 3000mg, etc.

[0007] The single-dose form mentioned in this invention refers to the specification of the active ingredient.

[0008] A pharmaceutical composition comprising: a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient, and an excipient, wherein the active ingredient comprises 1.0% to 85.0% by weight in the pharmaceutical composition;

[0009] In embodiments of the present invention, the active ingredient in the pharmaceutical composition comprises 2.0% to 85.0% by weight; preferably 5.0% to 85.0%; preferably 5.0% to 80.0%; more preferably 6.0% to 65.0%; more preferably 7.0% to 50.0%; more preferably 7.0% to 45.0%; more preferably 7.0% to 35.0%; more preferably 8.0% to 35.0%; more preferably 8.0% to 30.0%; more preferably 8.0% to 28.0%; more preferably 8.0% to 25.0%; more preferably 8.0% to 20.0%; more preferably 9.0% to 20.0%; more preferably 9.0% to 18.0%; more preferably 10.0% to 17.0%; more preferably 10.0% to 16.7%.

[0010] The "excipient" described in this invention, also known as a "pharmaceuticalally acceptable excipient," "excipient," or "additional agent," refers to all additional materials used in formulating prescriptions and manufacturing pharmaceuticals, excluding the active ingredient. It is generally a pharmaceutically acceptable inert ingredient that has undergone reasonable safety assessment. Examples of excipients, without limitation, include binders, disintegrants, lubricants, flow aids, stabilizers, fillers (or diluents), as well as flavoring agents, thickeners, dispersants, colorants, and fragrances. Excipients can enhance the handling characteristics of pharmaceutical formulations, for example, by increasing flowability and / or adhesion, making the formulation more suitable for direct compression. Furthermore, the "excipient" should have good compatibility with the active ingredient, meaning that the excipient itself or its impurities will not chemically react with the structural groups in the active ingredient or cause degradation of the active ingredient, resulting in a decrease in the content of the active ingredient. In some embodiments, the excipient comprises fillers and lubricants. In other embodiments, the excipient comprises fillers, lubricants, and disintegrants. In other embodiments, the excipients include fillers, lubricants, disintegrants, and flow aids.

[0011] The term "filler" as used in this invention refers to an excipient used to increase the weight and volume of a pharmaceutical composition to facilitate shaping and dispensing. The filler described in this invention can be a single filler or a mixture of two or more fillers. In some embodiments of this application, the filler is selected from one or more of starch, pregelatinized starch, powdered sugar, magnesium hydroxide, lactose, dextrin, silicified microcrystalline cellulose, microcrystalline cellulose, sugar alcohols, or inorganic calcium salts; preferably, the sugar alcohol is selected from one or more of xylitol, sorbitol, and mannitol; preferably, the inorganic calcium salt is selected from one or more of calcium phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate, calcium carbonate, and calcium sulfate, or their hydrates. In some embodiments, the filler is selected from one or more of pregelatinized starch, dextrin, silicified microcrystalline cellulose, microcrystalline cellulose, and mannitol (such as mannitol 100SD, 200SD, 200GT). In some embodiments, the filler is a combination of two fillers, such as a combination of microcrystalline cellulose and mannitol (e.g., mannitol 100SD, 200SD, 200GT), or a combination of siliconized microcrystalline cellulose and mannitol.

[0012] In some embodiments, the filler comprises 10.0% to 95.0% by weight in the pharmaceutical composition; preferably 30.0% to 90.0%; more preferably 50.0% to 90.0%; more preferably 50.0% to 85.0%; more preferably 60.0% to 85.0%; more preferably 65.0% to 85.0%; more preferably 70.0% to 85.0%; more preferably 70.0% to 83.0%; more preferably 72.0% to 83.0%; more preferably 72.0% to 80.0%; more preferably 72.7% to 79.3%.

[0013] In some embodiments, the filler is a combination of microcrystalline cellulose and mannitol (such as mannitol 100SD, 200SD, 200GT); the microcrystalline cellulose in the pharmaceutical composition comprises 10.0% to 95.0% by weight, preferably 40.0% to 90.0%, more preferably 50.0% to 85.0%, more preferably 55.0% to 80.0%, more preferably 60.0% to 80.0%, more preferably 60.0% to 78.0%, more preferably 62.0% to 80.0%, more preferably 65%. The mannitol content in the pharmaceutical composition is 1.0% to 80.0%, more preferably 2.0% to 60.0%, more preferably 2.0% to 30.0%, more preferably 2.0% to 10.0%, more preferably 2.0% to 8.0%, more preferably 3.0% to 7.0%, more preferably 4.0% to 6.0%, and more preferably 5.0%.

[0014] In some embodiments, microcrystalline cellulose and mannitol are added internally and externally; preferably, the internally added excipients are microcrystalline cellulose and mannitol, and the externally added excipient is microcrystalline cellulose.

[0015] In some embodiments, the added microcrystalline cellulose comprises 10.0% to 95.0% by weight in the pharmaceutical composition; preferably 25.0% to 90.0%; more preferably 40.0% to 90.0%; more preferably 40.0% to 80.0%; more preferably 45.0% to 70.0%; more preferably 50.0% to 65.0%; more preferably 55.0% to 62.0%; more preferably 55.0% to 61.6%.

[0016] In some embodiments, the added microcrystalline cellulose comprises 1.0% to 90.0% by weight in the pharmaceutical composition; preferably 5.0% to 80.0%; more preferably 6.0% to 60.0%; more preferably 7.0% to 40.0%; more preferably 8.0% to 30.0%; more preferably 9.0% to 20.0%; more preferably 10.0% to 15.0%; more preferably 12.0% to 13.0%; more preferably 12.7%.

[0017] In some embodiments, the added mannitol constitutes 1.0% to 90.0% by weight in the pharmaceutical composition; preferably 2.0% to 60.0%; more preferably 2.0% to 30.0%; more preferably 2.0% to 10.0%; more preferably 2.0% to 8.0%; more preferably 3.0% to 7.0%; more preferably 4.0% to 6.0%; more preferably 5.0%.

[0018] In some embodiments, the weight ratio of microcrystalline cellulose to mannitol is 1:100 to 100:1; preferably 1:50 to 50:1; more preferably 1:1 to 50:1; more preferably 1:1 to 25:1; more preferably 5:1 to 25:1; more preferably 5:1 to 20:1; more preferably 10:1 to 20:1; more preferably 12:1 to 18:1; more preferably 13:1 to 15:1.

[0019] In some embodiments, the weight ratio of internally added microcrystalline cellulose to internally added mannitol is 1:100 to 100:1; preferably 1:50 to 50:1; more preferably 1:1 to 50:1; more preferably 1:1 to 25:1; more preferably 5:1 to 25:1; more preferably 5:1 to 20:1; more preferably 8:1 to 20:1; more preferably 9:1 to 15:1; more preferably 11:1 to 13:1.

[0020] The "lubricating excipient" described in this invention is a broad term for lubricant. "Lubricant" refers to an excipient used to reduce friction between particles and between particles and die orifices in a pharmaceutical composition, thereby improving force transmission and distribution. Based on its functions of reducing friction, increasing particle flowability, and preventing adhesion between the die orifice and pharmaceutical particles, lubricating excipients are further classified into lubricants, flow aids, and anti-adhesion agents. In some embodiments of this application, the lubricating excipient comprises a lubricant and / or a flow aid.

[0021] The lubricant of the present invention is selected from one or more of stearic acid or its salts (e.g., magnesium stearate, calcium stearate, zinc stearate, sodium stearate fumarate), palmitic acid, glyceryl palmitate stearate, sodium benzoate, sodium lauryl sulfate, hydrogenated vegetable oil, talc, silica, micronized silica, sodium stearoyl fumarate, magnesium stearoyl fumarate, magnesium lauryl sulfate, or polyethylene glycol (e.g., polyethylene glycol 6000, polyethylene glycol 8000); preferably polyethylene glycol (e.g., polyethylene glycol 8000) or stearic acid. One or more of magnesium or sodium stearate; more preferably polyethylene glycol (e.g., polyethylene glycol 6000, polyethylene glycol 8000), magnesium stearate, sodium stearate, polyethylene glycol (e.g., polyethylene glycol 6000, polyethylene glycol 8000), magnesium stearate, polyethylene glycol (e.g., polyethylene glycol 6000, polyethylene glycol 8000), sodium stearate, magnesium stearate, and sodium stearate; more preferably one of magnesium stearate or sodium stearate; more preferably sodium stearate.

[0022] In some embodiments, the lubricant comprises 0.1% to 5.0% by weight in the pharmaceutical composition; preferably 0.5% to 4.0%; more preferably 0.6% to 2.3%; more preferably 0.6% to 2.0%; more preferably 0.6% to 1.8%; more preferably 0.6% to 1.5%; more preferably 1.0% to 1.5%; more preferably 0.2% to 0.6% internal lubricant and 0.3% to 0.9% external lubricant; more preferably 0.3% to 0.5% internal lubricant and 0.4% to 0.7% external lubricant; more preferably 0.4% internal lubricant and 0.6% external lubricant.

[0023] The flow aid described in this invention is selected from one or more of colloidal silica or aluminum hydroxide; preferably colloidal silica.

[0024] In some embodiments, the gliding agent is present in the pharmaceutical composition at a weight percentage of 0.0% to 10.0%; preferably 0.1% to 5.0%; more preferably 0.5% to 3.0%; more preferably 1.0% to 2.0%; more preferably 1.5% to 2.0%; and more preferably 1.7%.

[0025] The "disintegrant" described in this invention refers to an excipient used to promote the disintegration of a pharmaceutical composition in the gastrointestinal tract and increase the dissolution of the active ingredient. The disintegrant described in this invention is selected from one or more of carboxymethyl cellulose, powdered cellulose, potassium plucklein, sodium alginate, sodium starch glycolate, polyvinylpyrrolidone, maltodextrin, magnesium aluminum silicate, corn starch, pregelatinized starch, crospovidone (such as crospovidone CL-F, XL, XL-10, CL), low-substituted hydroxypropyl cellulose (such as low-substituted hydroxypropyl cellulose LH-31, LH-11, LH-21, LH-22, NBD-021), sodium carboxymethyl starch, or sodium crospovidone carboxymethyl cellulose, preferably corn starch, pregelatinized starch, or crospovidone carboxymethyl cellulose. One or more of the following: crospovidone (such as crospovidone CL-F, XL, XL-10, CL), low-substituted hydroxypropyl cellulose (such as low-substituted hydroxypropyl cellulose LH-31, LH-11, LH-21, LH-22, NBD-021), sodium carboxymethyl starch, or sodium crospovidone carboxymethyl cellulose, more preferably crospovidone (such as crospovidone CL-F, XL, XL-10, CL) or low-substituted hydroxypropyl cellulose (such as low-substituted hydroxypropyl cellulose LH-31, LH-11, LH-21, LH-22, NBD-021).

[0026] In some embodiments, the disintegrant in the pharmaceutical composition is 0.1% to 20.0% by weight; preferably 2.0% to 15.0%; more preferably 4.0% to 12.0%; more preferably 5.0% to 10.0%; more preferably 6.0% to 10.0%; more preferably 7.0% to 10.0%; more preferably 8.0% to 10.0%; more preferably 8.0% to 9.0%; more preferably 0.1% to 1.0% internal disintegrant and 5.0% to 9.0% external disintegrant; more preferably 0.5% to 1.0% internal disintegrant and 7.0% to 9.0% external disintegrant; more preferably 1.0% internal disintegrant and 7.0% external disintegrant.

[0027] Unless otherwise specified, all percentages are given as % by weight of the total weight of the pharmaceutical composition and its solid oral formulation.

[0028] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are: 1.0% to 85.0% of the active ingredient, 10.0% to 95.0% of the filler, 0.1% to 20.0% of the disintegrant, 0.1% to 5.0% of the lubricant, and 0% to 10% of other excipients, the sum of the weight percentages of the above components being 100%.

[0029] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are as follows: 6.0% to 65.0% of the active ingredient, 30.0% to 90.0% of the filler, 2.0% to 15.0% of the disintegrant, 0.5% to 4.0% of the lubricant, 0.0% to 10.0% of the flow aid, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0030] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are: 7.0% to 45.0% of the active ingredient, 50.0% to 85.0% of the filler, 4.0% to 12.0% of the disintegrant, 0.6% to 2.3% of the lubricant, 0.1% to 5.0% of the flow aid, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0031] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are as follows: 8.0% to 30.0% of the active ingredient, 60.0% to 85.0% of the filler, 5.0% to 10.0% of the disintegrant, 0.6% to 2.0% of the lubricant, 0.5% to 3.0% of the flow aid, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0032] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are as follows: 8.0% to 28.0% of the active ingredient, 65.0% to 85.0% of the filler, 5.0% to 10.0% of the disintegrant, 0.6% to 1.5% of the lubricant, 1.0% to 2.0% of the flow aid, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0033] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are as follows: 8.0% to 25.0% of the active ingredient, 70.0% to 83.0% of the filler, 5.0% to 10.0% of the disintegrant, 0.6% to 1.5% of the lubricant, 1.5% to 2.0% of the flow aid, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0034] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are: 8.0% to 20.0% of the active ingredient, 70.0% to 83.0% of the filler, 6.0% to 10.0% of the disintegrant (more preferably 8.0% to 10.0%), 1.0% to 1.5% of the lubricant, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0035] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are: 8.0% to 20.0% of the active ingredient, 70.0% to 83.0% of the filler, 6.0% to 10.0% of the disintegrant, 1.0% to 1.5% of the lubricant, 1.5% to 2.0% of the flow aid, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0036] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are as follows: 10.0% to 16.7% of the active ingredient, 72.7% to 79.3% of the filler, 8.0% to 10.0% of the disintegrant, 1.0% to 1.5% of the lubricant, 1.5% to 2.0% of the flow aid, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0037] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are as follows: 8.0% to 30.0% of the active ingredient, 60.0% to 80.0% of microcrystalline cellulose, 2.0% to 10.0% of mannitol, 5.0% to 10.0% of one of crospovidone or low-substituted hydroxypropyl cellulose, 0.6% to 2.3% of one or two of sodium stearate fumarate, polyethylene glycol, or magnesium stearate, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0038] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are as follows: 8.0% to 25.0% of the active ingredient, 60.0% to 78.0% of microcrystalline cellulose, 4.0% to 6.0% of mannitol, 6.0% to 10.0% of one of crospovidone or low-substituted hydroxypropyl cellulose, 1.0% to 1.5% of one or both of sodium stearate fumarate, polyethylene glycol, or magnesium stearate, 1.5% to 2.0% of colloidal silica, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0039] In some embodiments of this application, the components of the pharmaceutical composition and their weight percentages are as follows: 9.0% to 20.0% of the active ingredient, 62.0% to 78.0% of microcrystalline cellulose, 4.0% to 6.0% of mannitol, 6.0% to 10.0% of one of crospovidone or low-substituted hydroxypropyl cellulose, 1.0% to 1.5% of one of sodium stearate fumarate, polyethylene glycol, or magnesium stearate, 1.5% to 2.0% of colloidal silica, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

[0040] A second aspect of the invention provides a solid oral formulation made from the above-described pharmaceutical composition.

[0041] The "solid oral preparation" described in this invention refers to a solid pharmaceutical preparation for oral administration. This invention relates to solid oral preparations made from the above-mentioned pharmaceutical composition, preferably in the form of powders, capsules, tablets, granules, or fine granules, more preferably powders, capsules, or tablets, even more preferably tablets, even more preferably coated tablets, and most preferably film-coated tablets.

[0042] The "coating material," "coating powder," "coating agent," or "coating premix" described in this invention are mixtures of various pharmaceutical excipients, primarily used for coloring, masking odors, protecting against light, extending shelf life, and improving appearance. The "film-coated tablets" described in this invention refer to tablets with a film coating on the tablet core (which is prepared by compression of the pharmaceutical composition of this invention). The film coating can be prepared using coating materials and methods commonly used in the art. For example, film coating materials typically contain one or more of the following: film-forming agents (or polymeric materials), plasticizers, pore-forming agents, colorants, light-blocking agents, and certain solid materials; furthermore, the coating material can be dissolved in a solvent to form a coating solution. The polymer material can be selected from one or more of hydroxypropyl methylcellulose, hydroxypropyl cellulose, methylcellulose, hydroxyethylcellulose, acrylic resin, ethylcellulose, cellulose acetate, cellulose acetate phthalate, polyvinyl alcohol phthalate, cellulose acetate triterpenoid, hydroxypropyl methylcellulose phthalate, and polyvinyl alcohol; the plasticizer can be selected from glycerol, propylene glycol, polyethylene glycol, glycerol monoacetate, glycerol triacetate, dibutyl sebacate, dibutyl phthalate, diethyl phthalate, castor oil, silicone oil, corn oil, liquid paraffin, etc.; the pore-forming agent (also known as the release rate regulator) can be selected from sucrose, sodium chloride, surfactant, etc.; the solid material can be selected from talc, magnesium stearate, colloidal silica, etc.; the light-blocking agent includes titanium dioxide; and conventional colorants in the art can also be used as appropriate, such as the colorant selected from one or more of amaranth, carmine, tartrazine, soluble indigo, orange G, eosin, fuchsin, methylene blue, Sudan yellow, or mercurochrome. Alternatively, commercially available premixed coating powder can be used as the coating material, for example... Series of coating powders, Series of coating powders, Series of coating powders, Series of coating powders, A series of coating powders, etc. The coating material can be a gastrointestinal or enteric coating material; gastrointestinal Opadry is preferred. The film coating weight gain accounts for 1.0% to 10.0% of the tablet core weight, preferably 2.0% to 5.0%, and more preferably 2.0% to 4.0%. The coating solvent is selected from one or more of water or ethanol, preferably water, which can be removed during drying and does not remain in the final product. For example, The series of coating powder models include: Opal 85G64788, 85F18422, 0366507, 8568918, 85F12252, 03F58908, etc.

[0043] A third aspect of the present invention provides a method for preparing the above-mentioned pharmaceutical composition, comprising: (1) mixing the active ingredient and excipient in a mixing container to produce a premix; (2) dry granulation; and (3) mixing the obtained granules with the excipient to obtain the pharmaceutical composition.

[0044] In some embodiments, the method for preparing the pharmaceutical composition of the present invention includes: (1) preparing materials: weighing the compound of formula (I) or its pharmaceutically acceptable salt (i.e. the above active ingredient) and the corresponding excipient according to the prescription amount; (2) mixing the active ingredient, filler, disintegrant and lubricant in a mixing container to produce premix I, adding premix I to a granulator to granulate, taking the granulated mixture and adding it to a mixing tank to mix evenly to produce premix II, adding the lubricant to the mixing tank to mix evenly to produce premix III; (3) dry granulation; (4) adding the obtained granules and excipients other than lubricant to a mixing tank and mixing evenly to produce total mixture I, mixing the lubricant with total mixture I to produce total mixture II, and obtaining the pharmaceutical composition.

[0045] The method described above for preparing the pharmaceutical composition of the present invention may further include other steps not mentioned.

[0046] In some implementations, dry granulation involves pressing large tablets using a tablet press, then sieving and granulating these tablets. In other implementations, a dry granulator is used, and by adjusting appropriate horizontal feed speed, vertical feed speed, roller pressure, and roller gap, a suitable tablet density is obtained, which is then further pulverized to obtain dry-formed granules with suitable powder composition.

[0047] The term "mixing container" should be interpreted broadly, encompassing both flexible mixing containers (including but not limited to flexible bags such as clean plastic bags and self-sealing bags) and rigid mixing containers (including but not limited to hopper mixers). Those skilled in the art can select appropriate mixing containers for premixing and final mixing operations based on batch size and weight.

[0048] A fourth aspect of the present invention provides a method for preparing the above-mentioned solid oral dosage form, comprising: filling a packaging bag with the pharmaceutical composition obtained by the above preparation method according to the packaging dosage to form a powder; or filling the pharmaceutical composition into a capsule to form a capsule; or further compressing the pharmaceutical composition into a tablet using a suitable tableting machine.

[0049] In some embodiments, the pharmaceutical composition is directly compressed into tablets using a suitable tableting machine. The tablets have a target core weight, appropriate size, and compressibility.

[0050] The term "direct compression" as used herein refers to a method of directly compressing the components of a pharmaceutical preparation (i.e., the active ingredient and excipients) without altering the physical and chemical properties of the active ingredient. An exemplary direct compression method includes: mixing the active ingredient and excipients in powder form in a mixing apparatus; then filling the mixed composition into a mold and directly compressing it through a punch. Excipients useful in direct compression methods include, but are not limited to, fillers and lubricants.

[0051] In some embodiments, the tablet is further formulated into a coated tablet, preferably a film-coated tablet. In these embodiments, the tablet (i.e., the substrate prepared from the aforementioned pharmaceutical composition) serves as the core of the coated tablet. An exemplary method for preparing a film-coated tablet includes: (1) preparing a coating solution; (2) rotating the core in a coating pan to uniformly spray the coating solution onto it, thereby obtaining a film-coated tablet; and (3) drying the resulting film-coated tablet. The coating solution can be prepared by dispersing (e.g., dissolving or suspending) a coating material (e.g., a film-coating premix) in a coating solvent (e.g., water, preferably purified water) (e.g., at ambient temperature in a suitable mixer).

[0052] The fifth aspect of the invention provides the use of the above-described pharmaceutical composition or the above-described solid oral dosage form in the preparation of a medicament for the prevention and / or treatment of cardiovascular disease (CVD).

[0053] In one embodiment of the invention, the use of the above-described pharmaceutical composition or the above-described solid oral dosage form in the preparation of a medicament for the prevention and / or treatment of diseases or conditions associated with elevated Lp(a) plasma levels is provided.

[0054] In one embodiment of the invention, the disease or condition associated with elevated Lp(a) plasma levels is cardiovascular disease (CVD).

[0055] In one embodiment of the present invention, the cardiovascular disease (CVD) includes, but is not limited to, atherosclerotic cardiovascular disease (ASCVD), coronary artery stenosis, coronary artery-related disease, aortic stenosis, aortic stenosis-related disease, heart failure, heart failure-related disease, atrial fibrillation, and atrial fibrillation-related disease; the ASCVD includes peripheral vascular disease, peripheral artery-related disease, coronary heart disease, ischemic stroke, and ischemic stroke-related disease.

[0056] The term "elevated Lp(a) plasma level" in this invention refers to a plasma level equal to or higher than normal. For humans, "elevated Lp(a) plasma level" means a plasma level equal to or higher than approximately 30 mg / dL. In one embodiment of this invention, for humans, "elevated Lp(a) plasma level" is a plasma level equal to or higher than approximately 50 mg / dL. The compounds provided by this invention can be used for the treatment of lowering Lp(a) plasma levels.

[0057] In the application described, the compound of formula (I) or a pharmaceutically acceptable salt thereof may be the sole active ingredient of a medicament for treating cardiovascular disease (CVD) or a disease or condition associated with elevated Lp(a) plasma levels, or may be administered in combination with another medicament for treating cardiovascular disease (CVD) or a disease or condition associated with elevated Lp(a) plasma levels.

[0058] The sixth aspect of the present invention provides the above-described pharmaceutical composition or the above-described solid oral dosage form for the prevention and / or treatment of cardiovascular disease (CVD) or diseases or conditions associated with elevated Lp(a) plasma levels.

[0059] In one embodiment of the invention, the disease or condition associated with elevated Lp(a) plasma levels is cardiovascular disease (CVD).

[0060] In one embodiment of the present invention, the cardiovascular disease (CVD) includes, but is not limited to, atherosclerotic cardiovascular disease (ASCVD), coronary artery stenosis, coronary artery-related disease, aortic stenosis, aortic stenosis-related disease, heart failure, heart failure-related disease, atrial fibrillation, and atrial fibrillation-related disease; the ASCVD includes peripheral vascular disease, peripheral artery-related disease, coronary heart disease, ischemic stroke, and ischemic stroke-related disease.

[0061] In the above-described pharmaceutical compositions or solid oral formulations for the prevention and / or treatment of cardiovascular disease (CVD) or diseases or conditions associated with elevated Lp(a) plasma levels, the compound represented by formula (I) or a pharmaceutically acceptable salt thereof may be the sole active ingredient of a medicament for the treatment of cardiovascular disease (CVD) or diseases or conditions associated with elevated Lp(a) plasma levels, or may be administered in combination with other medicaments for the treatment of cardiovascular disease (CVD) or diseases or conditions associated with elevated Lp(a) plasma levels.

[0062] A seventh aspect of the present invention provides a method for preventing and / or treating cardiovascular disease (CVD) or diseases or conditions associated with elevated Lp(a) plasma levels, comprising administering the above-described pharmaceutical composition or the above-described solid oral preparation to a subject in need of it.

[0063] In one embodiment of the invention, the disease or condition associated with elevated Lp(a) plasma levels is cardiovascular disease (CVD).

[0064] In one embodiment of the present invention, the cardiovascular disease (CVD) includes, but is not limited to, atherosclerotic cardiovascular disease (ASCVD), coronary artery stenosis, coronary artery-related disease, aortic stenosis, aortic stenosis-related disease, heart failure, heart failure-related disease, atrial fibrillation, and atrial fibrillation-related disease; the ASCVD includes peripheral vascular disease, peripheral artery-related disease, coronary heart disease, ischemic stroke, and ischemic stroke-related disease.

[0065] In the methods for preventing and / or treating cardiovascular disease (CVD) or diseases or conditions associated with elevated Lp(a) plasma levels, the compound represented by formula (I) or a pharmaceutically acceptable salt thereof may be the sole active ingredient or may be administered in combination with other drugs for treating cardiovascular disease (CVD) or diseases or conditions associated with elevated Lp(a) plasma levels.

[0066] In embodiments of the present invention, the recipient may be a human or a non-human mammal, more preferably a human.

[0067] In embodiments of the present invention, the terms “comprising,” “including,” and “containing” generally have an open meaning, but within their scope also include closed meanings defined as “composed of.” For example, “a pharmaceutical composition comprising: a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient and an excipient” also includes “a pharmaceutical composition comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient and an excipient.”

[0068] Within the scope of this invention, various options for any feature can be combined with various options for other features to form a number of different embodiments. This invention is intended to encompass all possible embodiments comprised of various options for all technical features.

[0069] Within the scope of this invention, the amount of the compound as shown in formula (I) or its pharmaceutically acceptable salt in the prescription may be appropriately adjusted, or the ratio (mass ratio) with the excipient may be adjusted, to obtain pharmaceutical compositions or solid oral preparations containing different strengths or different drug weights, which also fall within the scope of this invention.

[0070] Within the scope of this invention, a weight percentage of 1.0% to 85.0% means that the two point values ​​of 1.0% and 85.0% and the range formed by the two point values ​​are included. Other weight percentage ranges in this invention should be understood in accordance with the above understanding.

[0071] Unless otherwise specified, the terms "pharmaceutically acceptable salt" or "medicinal salt" refer to a salt that, within reasonable medical judgment, is suitable for contact with mammalian, particularly human, tissues without excessive toxicity, irritation, allergic reactions, etc., and is proportionate to a reasonable benefit / risk ratio. Medically acceptable salts of amines, carboxylic acids, and other types of compounds are well known in the art. The salts can be prepared in situ during the final isolation and purification of the compounds of this invention, or solely by reacting a free base or free acid with a suitable reagent.

[0072] The beneficial effects of the present invention are one or more of the following:

[0073] The present invention relates to a composition, preparation method, and application of a substituted 2-(pyrrolidine-3-yl)acetic acid derivative having a reduced Lp(a) level. (1) The preparation method of the pharmaceutical composition is simple and does not have stringent requirements on the instruments, equipment, and operating processes used, making it more suitable for industrial production. (2) The pharmaceutical composition is suitable for direct compression tableting, which can greatly simplify the tablet preparation process. (3) Solid oral preparations such as tablets made from the pharmaceutical composition have favorable appearance, substrate hardness, friability, disintegration time, and uniformity of active ingredient content, meeting the formulation standards. (4) The pharmaceutical composition also has excellent stability. In the stability test, the related substances, content, moisture, dissolution, and crystal form of the pharmaceutical composition under investigation did not change significantly, making it suitable for long-term storage. Detailed Implementation

[0074] The present invention will be further illustrated below with reference to specific embodiments. It should be understood that these embodiments are for illustrative purposes only and are not intended to limit the scope of the invention. Experimental methods in the following embodiments, unless otherwise specified, are generally performed under conventional conditions or as recommended by the manufacturer. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as are familiar to those skilled in the art. Furthermore, any methods and materials similar to or equivalent to those described herein can be applied to the methods of the present invention. All other embodiments obtained by those skilled in the art based on the embodiments of the present invention without inventive effort are within the scope of protection of the present invention. The preferred embodiments and materials shown herein are for illustrative purposes only.

[0075] The starting materials used in the embodiments of the present invention are known and commercially available, or can be synthesized using or in accordance with methods known in the art.

[0076] Preparation Example 1: Preparation of Compound (I)

[0077] Step 1: Preparation of Intermediate 1

[0078] Anhydrous ethanol (5 L), SM1 (500 g), and SM2 (440 g) were added to a reaction vessel and stirred to dissolve. The temperature was controlled to not exceed 15 °C. Sodium borohydride (87 g) was added in portions, and the reaction was carried out at 25 ± 5 °C for 3 h after the addition was complete. Ethyl acetate and sodium chloride aqueous solution were added to the reaction vessel for extraction. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was subjected to silica gel column chromatography (ethyl acetate: n-heptane = 2:1) to give 730 g of the target product.

[0079] Step 2: Preparation of Intermediate 2

[0080] Ethyl acetate (7.3 L), intermediate 1 (730 g), SM3 (390 g), 1-ethyl-(3-dimethylaminopropyl)carbodiimide hydrochloride (200 g), 2-hydroxypyridine-N-oxide (120 g), and diisopropylethylamine (350 g) were added to a reaction vessel, and the mixture was stirred at room temperature for 20 h. Purified water was added to the reaction vessel for extraction. The organic phase was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure. The concentrate was subjected to silica gel column chromatography (n-heptane:ethyl acetate = 3:2) to give 1050 g of the target product.

[0081] Step 3: Preparation of compound (I)

[0082] Add 1,4-dioxane (4 L), purified water (1 L), intermediate 2 (1 kg), and hydrochloric acid (1 kg) to the reaction vessel and react at 65 ± 5 °C for 3 h. Adjust the pH to 6–7 with sodium hydroxide aqueous solution, then extract with dichloromethane. Concentrate under reduced pressure, add trifluoroethanol and stir to dissolve, filter, and concentrate the organic phase under reduced pressure. Add purified water (15 L) to the reaction vessel, stir to dissolve, and filter. Add N,N-dimethylformamide (19 L), then heat to 45–50 °C and maintain the temperature for crystallization for 15–50 h. Add acetone, cool to 25 ± 5 °C, and continue crystallization for 2 h. Filter, wash the filter cake with acetone, and dry to obtain 480 g of the target compound. LCMS (ESI) [M+H]+ = 769.56. 1H NMR (400 MHz, Deuterium) Oxide)δ7.08-7.24(m,4H),6.97-7.05(m,2H),6.88-6.95(dd,1H),6.73-6.85(m,3H) ,6.73-6.81(d,1H),6.62(s,1H),6.54-6.56(d,1H),4.47-4.51(m,2H),3.96(m,1H),3 .76-3.78(m,2H),3.39-3.70(m,6H),3.34-3.37(m,3H),3.16-3.20(m,3H),2.80-2.9 7(m,3H),2.62-2.76(m,9H),2.47-2.56(m,3H),2.08-2.09(m,3H),1.68-1.70(m,3H).

[0083] Example 1: Raw material compatibility test

[0084] The compatibility of the compound of formula (I) obtained in Preparation Example 1 with the excipients to be used, namely microcrystalline cellulose, mannitol, silicified microcrystalline cellulose, colloidal silica, sodium stearate fumarate, magnesium stearate, polyethylene glycol, crospovidone, pregelatinized starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, and Opadry, a film coating premix (gastric-soluble type), was investigated. Specifically, the following API compounds were investigated: API: mannitol (1:5), API: microcrystalline cellulose (1:5), API: silicified microcrystalline cellulose (1:5), API: crospovidone (1:1), API: low-substituted hydroxypropyl cellulose (1:5), API: pregelatinized starch (1:15), API: sodium carboxymethyl starch (1:5), API: colloidal silica (1:1), API: sodium stearate fumarate (1:1), API: magnesium stearate (1:1), API: polyethylene glycol 8000 (1:1), and API: film-coating premix (gastric-soluble) Opadry (1:1). These compounds were placed at 60°C (sealed) under 4500±500 lux of light and accelerated 40°C / 75% RH (open) conditions for 30 days, and then at 92.5% RH (open) under high humidity conditions for 14 days. Samples were taken and the properties of relevant substances were analyzed. Among these, API refers to compounds of formula (I).

[0085] Experimental results show that the mixture of raw materials, excipients and active pharmaceutical ingredients used in this product did not undergo significant changes in related substances under high temperature, high humidity, light, and accelerated conditions, indicating that the excipients and raw materials have good compatibility.

[0086] Example 2: Preparation of substrate (10mg specification) of compound (I)

[0087] The tablet prescription is shown in the table below:

[0088] Table 1. Prescription for 10mg tablets

[0089] The dry granulation process was used for preparation, and the process parameters and steps are shown in the table below:

[0090] Table 2 Process parameters and process steps

[0091] The results showed that the tableting process went smoothly, and the resulting tablet samples showed no obvious wear on the surface and edges. The appearance, friability, and content uniformity all met the requirements. Specific results are shown in the table below:

[0092] Table 3 Detection Results

[0093] Note: "~" indicates approximately.

[0094] Example 3: Preparation of substrates (50 mg and 100 mg) of compound (I)

[0095] Using a dry granulation process, referring to the process parameters and steps of Example 2, tablets of 50mg and 100mg strengths were prepared with a hardness range of 15–30 kg for 50mg and 25–35 kg for 100mg. The tablet formulations are shown in the table below.

[0096] Table 4. Prescriptions for 50mg and 100mg tablets

[0097] The results showed that the tableting process went smoothly, and the tablet samples of both formulations showed no obvious wear on the surface and edges. The appearance, friability, and content uniformity all met the requirements. The specific results are shown in the table below:

[0098] Table 5 Test Results

[0099] Note: "~" indicates approximately.

[0100] Example 4: Investigation of fillers

[0101] The effects of fillers on the powder properties of premixed particles, the mixing uniformity of premixed particles, and the mixing uniformity of total mixed particles were investigated. The results are as follows:

[0102] Table 6. Results of the investigation of fillers

[0103] The results showed that when microcrystalline cellulose and mannitol were used as fillers, the substrate had a good appearance and the particle mixing uniformity was good.

[0104] Example 5: Investigation of disintegrants

[0105] Different types of disintegrants were screened, and the results are shown in the table below:

[0106] Table 7. Screening Results of Disintegrant Types Note: "~" indicates approximately.

[0107] The results showed that both crospovidone and low-substituted hydroxypropyl cellulose could meet the disintegration requirements.

[0108] Example 6: Investigation of disintegrants

[0109] Taking crospovidone as an example of a disintegrant, the dosage was screened, and the results are shown in the table below:

[0110] Table 8. Screening results for disintegrant dosage. Note: "~" indicates approximately.

[0111] The results showed that a crosslinked polyvinylpyrrolidone dosage of 5% to 10% could achieve relatively good compressibility and a good disintegration time, with a preferred dosage of 6% to 10%, and a more preferred dosage of 8% to 10%.

[0112] Example 7: Investigation of Lubricants

[0113] The feasibility of tableting processes, appearance, and disintegration were used as indicators to study the effects of lubricants polyethylene glycol 8000, magnesium stearate, and sodium stearate fumarate. The results are as follows:

[0114] Table 9. Results of Lubricant Type and Dosage Screening Note: "~" indicates approximately.

[0115] The results showed that when one or more of polyethylene glycol 8000, magnesium stearate, and sodium stearate fumarate were used as lubricants, the substrates had a satisfactory or good appearance and a good disintegration time.

[0116] Example 8: Investigation of Lubricants

[0117] Using process feasibility and disintegration as indicators, the dosage of lubricants was investigated. Taking sodium stearate fumarate as an example, the results are shown in the table below:

[0118] Table 10 Results of Lubricant Dosage Study Note: "~" indicates approximately.

[0119] The results showed that the amount of sodium stearate fumarate at 1.0-1.5% had no effect on product disintegration and the substrate had a better appearance.

[0120] Example 9: Study on weight gain of coating

[0121] The substrate was coated using Opadry, a premixed film coating agent (gastric-soluble type). The effects of weight gain of approximately 2%, 3%, and 5% on product appearance and dissolution were investigated. The results are shown in the table below:

[0122] Table 11 Results of the weight gain of samples with different coatings

[0123] The test results show that when the coating weight gain is in the range of 2% to 5%, the appearance of the coated tablets meets the requirements, and when the coating weight gain is 3% and 5%, the dissolution rate is greater than 85% at 30 min.

[0124] Example 10: Preparation of tablets of compound (I)

[0125] Substrates of various specifications were prepared according to the process parameters and steps of Examples 2 or 3. The substrates were coated with a film-coating premix (gastric-soluble type) Opadryl as the coating material. The tablet bed temperature was 40-52℃, and the coating weight gain was 2.0%–4.0%. The tablet formulations are shown in the table below:

[0126] Table 12 Prescriptions for Tablets of Various Specifications

[0127] Table 13 Tablet Test Results

[0128] The results showed that the tablets of each specification had smooth surfaces, and the related substances, moisture, dissolution and content all met the requirements. The specific results are shown in Table 13.

[0129] Example 11: Stability Study of Film-Coated Tablets

[0130] The 10mg and 100mg tablets from Example 10 were selected, packaged in aluminum foil bags, and placed under accelerated testing conditions (40℃±2℃ / 75%±5%RH) for 3 months. Samples were taken at 1 and 3 months, and the results are shown in Tables 14-15.

[0131] Table 14 Results of accelerated packaging of 10mg tablets in aluminum foil bags under accelerated conditions (40℃±2℃ / 75%±5%RH)

[0132] Table 15 Results of accelerated packaging of 100mg tablets in aluminum foil bags under accelerated conditions (40℃±2℃ / 75%±5%RH)

[0133] Conclusion: When the 10mg and 100mg products (aluminum foil bag packaging) were placed under accelerated test conditions (40℃±2℃ / 75%±5%RH) for 3 months, compared with day 0, the appearance, moisture, related substances, dissolution and content were basically the same, and no obvious increase trend was observed. The crystal form did not change.

[0134] Example 12: Stability Study of Film-Coated Tablets

[0135] Tablets in 10 mg and 100 mg specifications were prepared according to the method of Example 10. They were packaged in aluminum foil bags and bottles with desiccant. They were placed under accelerated testing conditions (40℃±2℃ / 75%±5%RH) for 6 months, and samples were taken at 1, 3 and 6 months. The results are shown in Tables 16-19. They were placed under long-term testing conditions (25℃±2℃ / 60%±5%RH) for 9 months, and samples were taken at 1, 3, 6, 9 and 12 months. The results are shown in Tables 20-23.

[0136] Table 16 Results of accelerated packaging of 10mg tablets in aluminum foil bags under accelerated conditions (40℃±2℃ / 75%±5%RH)

[0137] Table 17 Results of accelerated packaging conditions (40℃±2℃ / 75%±5%RH) for 10mg tablet vials with desiccant

[0138] Table 18 Results of accelerated packaging of 100mg tablets in aluminum foil bags under accelerated conditions (40℃±2℃ / 75%±5%RH)

[0139] Table 19 Results of accelerated packaging conditions (40℃±2℃ / 75%±5%RH) for 100mg tablet vials with desiccant

[0140] Table 20 Results of long-term conditions (25℃±2℃ / 60%±5%RH) for 10mg tablets packaged in aluminum foil bags

[0141] Table 21 Results of long-term packaging conditions (25℃±2℃ / 60%±5%RH) for 10mg tablet vials with desiccant

[0142] Table 22 Results of long-term conditions (25℃±2℃ / 60%±5%RH) for 100mg tablets packaged in aluminum foil bags

[0143] Table 23 Results of long-term packaging conditions (25℃±2℃ / 60%±5%RH) for 100mg tablet vials with desiccant.

[0144] Conclusion: When the 10mg and 100mg products in aluminum foil bags and bottles with desiccant were placed under accelerated testing (40℃±2℃ / 75%±5%RH) for 6 months and under long-term testing (25℃±2℃ / 60%±5%RH) for 12 months, the appearance, moisture content, related substances, dissolution rate, and content were basically consistent with those at day 0, and no obvious increasing trend was observed.

[0145] Biological test evaluation

[0146] Test Example 1: Lp(a) Assembly Inhibition Screening ELISA Detection Experiment

[0147] 1. Reagents, consumables, and instruments

[0148] 2. Preparation of cell culture medium

[0149] 2.1 Complete cell culture medium

[0150] 2.2 Experimental Culture Medium

[0151] 3 Experimental Steps

[0152] 3.1 Cell Culture and Passaging

[0153] 1) Preheat the culture medium, DPBS, and trypsin in a 37℃ water bath.

[0154] 2) Digest cells with trypsin, transfer the cell suspension to a 15ml centrifuge tube, and centrifuge at 1000rpm for 5 minutes.

[0155] 3) Resuspend the cells in the culture medium and transfer the cell suspension to a new T75 cell culture flask.

[0156] 4) Incubate at 37℃ in a 5% CO2 incubator.

[0157] 3.2 Plate laying and chemical dosing

[0158] 1) Seed HepG2 cells overexpressing ApoA protein into 96-well plates, 100 μl per well, and culture overnight for adhesion.

[0159] 2) On the second day, replace the culture medium with fresh one, then add the diluted compound, and place the cell plate in a 5% CO2, 37°C constant temperature incubator for 24 hours.

[0160] 3.3 Preparation of cell culture supernatant

[0161] 1) Add 10 μl of 1.5 M EACA to each well.

[0162] 2) Centrifuge at 1000 rpm for 1 minute and transfer 100 μl of cell culture supernatant to a pre-coated ELISA plate.

[0163] 3.4 ELISA Experiment

[0164] 1) Add 100 μl of capture antibody to each well to pre-coat the ELISA plate and incubate overnight at 25°C.

[0165] 2) Add 300 μl of cleaning solution to each well and wash 5 times, one minute each time.

[0166] 3) Add 100 μl of blocking solution to each well and incubate at 25°C for 2 hours.

[0167] 4) Add 300 μl of cleaning solution to each well and wash 5 times, one minute each time.

[0168] 5) Add 100 μl of sample to each well and incubate at 25°C for 1 hour.

[0169] 6) Add 300 μl of cleaning solution to each well and wash 5 times, one minute each time.

[0170] 7) Add 100 μl of detection antibody to each well and incubate at 25°C for 1 hour.

[0171] 8) Add 300 μl of cleaning solution to each well and wash 5 times, one minute each time.

[0172] 9) Add 100 μl of substrate solution (Color Reagent A:Color Reagent B, 1:1) to each well and incubate at 25°C in the dark for 20 minutes.

[0173] 10) Add 50 μl of stop solution to each well, gently blow and aspirate several times with the pipette tip, and take the reading within five minutes.

[0174] 4.IC 50 Data analysis H=Ave(DMSO or H2O) L=Ave(1uM Reference) SD(H)=STDEV(DMSO or H2O) SD(L)=STDEV(1uM Reference) CV%(DMSO)=100*(SD_H / Ave_H) CV%(1uM Reference)=100*SD_L / Ave_L Z'=1-3*(SD_H+SD_L) / (Ave_H-Ave_L) Inhibition%=(Ave_H-Sample) / (Ave_H-Ave_L)

[0175] Compound IC 50 Nonlinear fitting regression equation: Y=Bottom+(Top-Bottom) / (1+10^((LogIC)) 50 -X)*HillSlope))

[0176] X:cpd concentration

[0177] Y:inhibition%

[0178] Top and Bottom:Plateaus in same units as Y

[0179] logIC 50 Same log units as X

[0180] HillSlope:Slope factor or Hill slope

[0181] 5. Experimental Results: The compounds of this invention exhibit a strong inhibitory effect on Lp(a) assembly, which is superior to that of the reference compound LY3473329. The results are shown in the table below.

[0182] Table 24 Note: LY3473329 is the compound in Example 1 of CN114008021A, and the preparation method is as described in Example 1 of patent CN114008021A.

[0183] Test Example 2: In vivo pharmacokinetic experiment of C57BL / 6J female mice

[0184] Using C57BL / 6J female mice as test animals, the drug concentration in plasma of C57BL / 6J female mice at different time points after intravenous and gavage administration of the compound was determined by LC / MS / MS, and the pharmacokinetic characteristics of the compound in C57BL / 6J female mice were studied.

[0185] Experimental animals: C57BL / 6J female mice

[0186] Drug preparation: Weigh a certain amount of the compound and add physiological saline to prepare colorless and clear solutions of 0.4 mg / mL (IV) and 1 mg / mL (PO).

[0187] Experimental Procedure: C57BL / 6J female mice were fasted overnight before being administered the drug via gavage, while intravenous administration was administered without fasting. The intravenous dose was 2 mg / kg, and the gavage dose was 10 mg / kg. Approximately 0.03 mL of blood was collected from the orbital venous plexus at 0.083 (IV), 0.25, 0.5, 1, 2, 4, 8, and 24 hours after administration. The blood samples were placed in centrifuge tubes containing EDTA-K2 and centrifuged at 3000 rpm / min for 10 min at 2-8°C to obtain plasma, which was then stored at -80°C.

[0188] Determination of the content of the target compound in the plasma of female C57BL / 6J mice at different blood collection time points: 10 μL of plasma from female C57BL / 6J mice collected at various time points after drug administration of LY3473329 and the compound of this application was added to 200 μL of 500 mM trichloroacetic acid aqueous solution to precipitate proteins, which contained 100 ng / mL internal standard. The mixture was vortexed for 1 min. Samples treated in test tubes were centrifuged at 14000 rpm for 7 min, and samples treated in 96-well plates were centrifuged at 4000 rpm for 10 min. 190 μL of supernatant was transferred to a 96-well plate, and 8 μL of supernatant was injected for LC-MS / MS analysis. Example 6 (WO2023078333A1): 12 μL of plasma from female C57BL / 6J mice collected at various time points after drug administration was added to 240 μL of methanol to precipitate proteins. The methanol contained 10 ng / mL internal standard. The mixture was vortexed for 1 min. Samples treated in test tubes were centrifuged at 14000 rpm for 7 min, and samples treated in 96-well plates were centrifuged at 4000 rpm for 10 min. 220 μL of the supernatant was transferred to a 96-well plate, and 10 μL of the supernatant was analyzed by LC-MS / MS.

[0189] Pharmacokinetic parameters

[0190] After detecting blood drug concentrations by LC / MS / MS analysis, pharmacokinetic parameters (such as Cmax, AUC, T1 / 2, etc.) were calculated using WinNonlin software and a non-compartmental model method.

[0191] The results showed that the compounds of this invention exhibited good pharmacokinetics, with better blood drug exposure after intravenous and gavage administration, a longer half-life, and excellent oral administration performance. Their pharmacokinetic properties, such as blood drug exposure and half-life, were superior to those of the control compounds LY3473329 and WO2023078333A1 (Compound of Example 6). The pharmacokinetic parameters of the compounds of formula (I) in C57BL / 6J female mice after gavage and intravenous administration are shown in the table below.

[0192] Among them, LY3473329 is the compound of Example 1 in CN114008021A, and the preparation method is the same as that of Example 1 in patent CN114008021A. The preparation method of the compound of Example 6 in WO2023078333A1 is the same as that of Example 6 in patent WO2023078333A1.

[0193] Table 25C57BL / 6J female mice administered pharmacokinetic parameters via gavage

[0194] Table 26C57BL / 6J female mice after intravenous administration of pharmacokinetic parameters

[0195] Test Example 3: Lp(a) Inhibition Test in Humanized Mice

[0196] The in vivo activity of the compound in reducing Lp(a) was evaluated in a humanized Lp(a) transgenic mouse model. Lp(a) mice were obtained by mating mice expressing humanized apoB 100 and mice expressing humanized apo(a) containing 16 Kringle repeats. Female mice aged 8–9 weeks were selected for the experiment. Housing conditions included a standard light cycle (12 hours light / 12 hours dark), temperature of 20–25°C, humidity of 40–70%, and free access to water and a normal diet.

[0197] The day before the experiment, mice were randomly divided into a solvent control group and a test compound group (n=5 / group) based on their body weight and baseline plasma Lp(a) concentration. Mice were orally administered either the solvent (physiological saline, 10 mL / kg) or the test compound (prepared with physiological saline to a concentration of 3 mg / mL, 10 mL / kg per mouse) once daily (9:00 am) for 3 consecutive days. Blood samples were collected after each 3-day course to measure the rate of change in serum Lp(a). Eight hours after the last administration, a 10 μL blood sample was collected from the tail and transferred to a 1.5 mL centrifuge tube containing 90 μL of physiological saline. The sample was thoroughly mixed and incubated on ice for 30 minutes. The sample was then centrifuged at 3000 rpm for 10 minutes at 4°C, and the supernatant was collected and placed on ice. A double-antibody sandwich ELISA assay was used to detect the Lp(a) concentration in the supernatant. Anti-Apo(a) capture antibody and HRP-conjugated anti-ApoB detection antibody were used. TMB was used for color development, and the reaction was terminated with 1N sulfuric acid. The OD value was read at 450 nm using a Tecan microplate reader. Calculate the inhibition rate for each treatment group. Inhibition rate (%) = (Pre-treatment Lp(a) concentration of solvent control group or self-administered drug - Post-treatment Lp(a) concentration) / Pre-treatment Lp(a) concentration of solvent control group or self-administered drug * 100.

[0198] The experimental results show that the compound of the present invention significantly reduces the serum Lp(a) level in mice in vivo.

[0199] The compounds of this invention significantly reduced serum Lp(a) levels in mice more effectively than the control compounds LY3473329 and / or WO2023078333A1, the compound of Example 6.

[0200] The inhibition rates of Lp(a) in vivo by compound (I) are shown in the table below.

[0201] Table 27 Single-dose in vivo efficacy test in mice

Claims

1. A pharmaceutical composition comprising: as an active ingredient, a compound represented by formula (I) or a pharmaceutically acceptable salt thereof, and an excipient, the weight percentage of the active ingredient in the pharmaceutical composition being 1.0% to 85.0%; ###00001### 2. A pharmaceutical composition comprising: as an active ingredient a compound represented by the formula (I) or a pharmaceutically acceptable salt thereof and an excipient, which is formulated into a single dose form, wherein the single dose form contains 0.001 mg to 3000 mg of the compound (I); 3. Pharmaceutical composition according to claim 2, characterized in that: The single-dose formulation comprises 0.001 mg to 2000 mg of compound (I); preferably 0.1 mg to 1800 mg of compound (I); more preferably 0.1 mg to 1500 mg of compound (I); more preferably 0.1 mg to 1000 mg of compound (I); more preferably 0.1 mg to 800 mg of compound (I); more preferably 1 mg to 500 mg of compound (I); more preferably 1 mg to 200 mg of compound (I); more preferably 1 mg to 100 mg of compound (I); more preferably 5 mg to 500 mg of compound (I); more preferably 10 mg to 500 mg of compound (I); more preferably 10 mg to 200 mg of compound (I); more preferably 10 mg to 100 mg of compound (I); or The single-dose pharmaceutical composition comprises a compound of formula (I) or a pharmaceutically acceptable salt thereof in the following amounts: 0.1 mg, 0.2 mg, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 2.5 mg, 5 mg, 7.5 mg, 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg, 95 mg, 100 mg, 120 mg, 125 mg. , 140mg, 150mg, 160mg, 170mg, 175mg, 180mg, 200mg, 220mg, 240mg, 250mg, 260mg, 280mg, 300mg, 350mg, 400mg, 450m g, 500mg, 600mg, 700mg, 800mg, 900mg, 1000mg, 1200mg, 1400mg, 1500mg, 1600mg, 1800mg, 2000mg, 2500mg, 3000mg.

4. Pharmaceutical composition according to any one of claims 1 to 3, characterized in that: The excipient comprises fillers and lubricants; or The excipients include fillers, lubricants, and disintegrants; or The excipients include fillers, lubricants, disintegrants, and flow aids; and / or The filler is selected from one or more of starch, pregelatinized starch, powdered sugar, magnesium hydroxide, lactose, dextrin, silicified microcrystalline cellulose, microcrystalline cellulose, sugar alcohols, or inorganic calcium salts; preferably, the sugar alcohol is selected from one or more of xylitol, sorbitol, and mannitol; preferably, the inorganic calcium salt is selected from one or more of calcium phosphate, calcium hydrogen phosphate, calcium dihydrogen phosphate, calcium carbonate, and calcium sulfate, or their hydrates; or The filler is selected from one or more of pregelatinized starch, dextrin, silicified microcrystalline cellulose, microcrystalline cellulose, and mannitol (such as mannitol 100SD, 200SD, 200GT); or The filler is a combination of two fillers, such as a combination of microcrystalline cellulose and mannitol (such as mannitol 100 SD, 200 SD, 200 GT), or a combination of silicified microcrystalline cellulose and mannitol; and / or The lubricant is selected from one or more of stearic acid or a salt thereof (e.g., magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate), palmitic acid, glyceryl palmitostearate, sodium benzoate, sodium lauryl sulfate, hydrogenated vegetable oil, talc, silicon dioxide, colloidal silicon dioxide, sodium stearyl fumarate, magnesium stearate, calcium stearate, magnesium lauryl sulfate, or polyethylene glycol (such as polyethylene glycol 8000); preferably one or more of polyethylene glycol (such as polyethylene glycol 8000), magnesium stearate, or sodium stearyl fumarate; further preferably one or more of polyethylene glycol (such as polyethylene glycol 6000, polyethylene glycol 8000), magnesium stearate, sodium stearyl fumarate, polyethylene glycol (such as polyethylene glycol 6000, polyethylene glycol 8000) and magnesium stearate, polyethylene glycol (such as polyethylene glycol 6000, polyethylene glycol 8000) and sodium stearyl fumarate, magnesium stearate and sodium stearyl fumarate; further preferably one of magnesium stearate or sodium stearyl fumarate; further preferably sodium stearyl fumarate; and / or The glidant is selected from one or more of colloidal silicon dioxide or aluminum hydroxide; preferably colloidal silicon dioxide; and / or The disintegrant is selected from one or more of carboxymethylcellulose, powdered cellulose, polacrilin potassium, sodium alginate, sodium starch glycolate, polyvinylpyrrolidone, maltodextrin, magnesium aluminometasilicate, corn starch, pregelatinized starch, crosscarmellose sodium (such as crosscarmellose sodium CL-F, XL, XL-10, CL), low-substituted hydroxypropylcellulose (such as low-substituted hydroxypropylcellulose LH-31, LH-11, LH-21, LH-22, NBD-021), sodium starch glycolate, or crosscarmellose sodium; preferably one or more of corn starch, pregelatinized starch, crosscarmellose sodium (such as crosscarmellose sodium CL-F, XL, XL-10, CL), low-substituted hydroxypropylcellulose (such as low-substituted hydroxypropylcellulose LH-31, LH-11, LH-21, LH-22, NBD-021), sodium starch glycolate, or crosscarmellose sodium; further preferably one or more of crosscarmellose sodium (such as crosscarmellose sodium CL-F, XL, XL- 10, CL) or low-substituted hydroxypropylcellulose (such as low-substituted hydroxyp ropylcellulose LH-31, LH-11, LH-21, LH-22,NBD-021).

5. Pharmaceutical composition according to any one of claims 1 to 4, characterized in that: The components of the pharmaceutical composition and their weight percentages are: The active ingredient in the pharmaceutical composition is 2.0% to 85.0%; preferably 5.0% to 85.0%; preferably 5.0% to 80.0%; further preferably 6.0% to 65.0%; further preferably 7.0% to 50.0%; further preferably 7.0% to 45.0%; further preferably 7.0% to 35.0%; further preferably 8.0% to 35.0%; further preferably 8.0% to 30.0%; further preferably 8.0% to 28.0%; further preferably 8.0% to 25.0%; further preferably 8.0% to 20.0%; further preferably 9.0% to 20.0%; further preferably 9.0% to 18.0%; further preferably 10.0% to 17.0% by weight; and / or The filler in the pharmaceutical composition is 10.0% to 95.0%; preferably 30.0% to 90.0%; further preferably 50.0% to 90.0%; further preferably 50.0% to 85.0%; further preferably 60.0% to 85.0%; further preferably 65.0% to 85.0%; further preferably 70.0% to 85.0%; further preferably 70.0% to 83.0%; further preferably 72.0% to 83.0%; further preferably 72.0% to 80.0%; or The filler is a combination of microcrystalline cellulose and mannitol (such as mannitol 100SD, 200SD, 200GT); the microcrystalline cellulose in the pharmaceutical composition is 10.0% to 95.0%, preferably 40.0% to 90.0%, further preferably 50.0% to 85.0%, further preferably 55.0% to 80.0%, further preferably 60.0% to 80.0%, further preferably 60.0% to 78.0%, further preferably 62.0% to 80.0%, further preferably 65.0% to 80.0%, further preferably 67.0% to 78.0%, further preferably 62.0% to 76.0%, further preferably 67.7% to 74.3% by weight; the mannitol in the pharmaceutical composition is 1.0% to 90.0%, preferably 2.0% to 60.0%, further preferably 2.0% to 30.0%, further preferably 2.0% to 10.0%, further preferably 2.0% to 8.0%, further preferably 3.0% to 7.0%, further preferably 4.0% to 6.0% by weight; and / or The lubricant in the pharmaceutical composition is 0.1% to 5.0%; preferably 0.5% to 4.0%; further preferably 0.6% to 2.3%; further preferably 0.6% to 2.0%; further preferably 0.6% to 1.8%; further preferably 0.6% to 1.5%; further preferably 1.0% to 1.5% by weight; and / or The lubricant in the pharmaceutical composition is 0.1% to 5.0%; preferably 0.5% to 4.0%; further preferably 0.6% to 2.3%; further preferably 0.6% to 2.0%; further preferably 0.6% to 1.8%; further preferably 0.6% to 1.5%; further preferably 1.0% to 1.5% by weight; The weight percentage of the glidant in the pharmaceutical composition is 0.0% to 10.0%; preferably 0.1% to 5.0%; further preferably 0.5% to 3.0%; further preferably 1.0% to 2.0%; further preferably 1.5% to 2.0%; and / or The weight percentage of the disintegrant in the pharmaceutical composition is 0.1% to 20.0%; preferably 2.0% to 15.0%; further preferably 4.0% to 12.0%; further preferably 5.0% to 10.0%; further preferably 6.0% to 10.0%; further preferably 7.0% to 10.0%; further preferably 8.0% to 10.0%; further preferably 8.0% to 9.0%; further preferably 0.1% to 1.0% of disintegrant inside and 5.0% to 9.0% of disintegrant outside; further preferably 0.5% to 1.0% of disintegrant inside and 7.0% to 9.0% of disintegrant outside.

6. Pharmaceutical composition according to any one of claims 1 to 5, characterized in that: The filler is microcrystalline cellulose and mannitol, and the weight ratio of the microcrystalline cellulose and mannitol is 1:100 to 100:1; preferably 1:50 to 50:1; more preferably 1:1 to 50:1; more preferably 1:1 to 25:1; more preferably 5:1 to 25:1; more preferably 5:1 to 20:1; more preferably 10:1 to 20:1; more preferably 12:1 to 18:1; more preferably 13:1 to 15:1; or The microcrystalline cellulose and mannitol are added in an inside and outside manner; preferably, the inside excipient is microcrystalline cellulose and mannitol, and the outside excipient is microcrystalline cellulose; further preferably, the weight ratio of the inside microcrystalline cellulose and the inside mannitol is 1:100 to 100:1; more preferably 1:50 to 50:1; more preferably 1:1 to 50:1; more preferably 1:1 to 25:1; more preferably 5:1 to 25:1; more preferably 5:1 to 20:1; more preferably 8:1 to 20:1; more preferably 9:1 to 15:1; more preferably 11:1 to 13:

1.

7. Pharmaceutical composition according to any one of claims 1 to 6, characterized in that: The components of the pharmaceutical composition and their weight percentages are: 1.0% to 85.0% of active ingredient, 10.0% to 95.0% of filler, 0.1% to 20.0% of disintegrant, 0.1% to 5.0% of lubricant, and 0% to 10% of other excipients, and the sum of the weight percentages of the above components is 100%; or The components of the pharmaceutical composition and their weight percentages are: 1.0% to 85.0% of active ingredient, 10.0% to 95.0% of filler, 0.1% to 20.0% of disintegrant, 0.1% to 5.0% of lubricant, and 0% to 10% of other excipients, and the sum of the weight percentages The components and their weight percentages of the pharmaceutical composition are: 7.0% to 45.0% of the active ingredient, 50.0% to 85.0% of the filler, 4.0% to 12.0% of the disintegrant, 0.6% to 2.3% of the lubricant, 0.1% to 5.0% of the glidant, and 0% to 5% of other excipients, and the sum of the weight percentages of the above components is 100%; or The components and their weight percentages of the pharmaceutical composition are: 8.0% to 30.0% of the active ingredient, 60.0% to 85.0% of the filler, 5.0% to 10.0% of the disintegrant, 0.6% to 2.0% of the lubricant, 0.5% to 3.0% of the glidant, and 0% to 5% of other excipients, and the sum of the weight percentages of the above components is 100%; or The components and their weight percentages of the pharmaceutical composition are: 8.0% to 28.0% of the active ingredient, 65.0% to 85.0% of the filler, 5.0% to 10.0% of the disintegrant, 0.6% to 1.5% of the lubricant, 1.0% to 2.0% of the glidant, and 0% to 5% of other excipients, and the sum of the weight percentages of the above components is 100%; or The components and their weight percentages of the pharmaceutical composition are: 8.0% to 25.0% of the active ingredient, 70.0% to 83.0% of the filler, 5.0% to 10.0% of the disintegrant, 0.6% to 1.5% of the lubricant, 1.5% to 2.0% of the glidant, and 0% to 5% of other excipients, and the sum of the weight percentages of the above components is 100%; or The components and their weight percentages of the pharmaceutical composition are: 8.0% to 20.0% of the active ingredient, 70.0% to 83.0% of the filler, 6.0% to 10.0% of the disintegrant (more preferably 8.0% to 10.0%), 1.0% to 1.5% of the lubricant, and 0% to 5% of other excipients, and the sum of the weight percentages of the above components is 100%; or The components and their weight percentages of the pharmaceutical composition are: 8.0% to 20.0% of the active ingredient, 70.0% to 83.0% of the filler, 6.0% to 10.0% of the disintegrant (more preferably 8.0% to 10.0%), 1.0% to 1.5% of the lubricant, and 0% to 5% of other excipients, and the sum of the weight percentages of the above components is 100%; or The components and their weight percentages of the pharmaceutical composition are: 8.0% to 20.0% of the active ingredient, 70.0% to 83.0% of the filler, 6.0% to 10.0% of the disintegrant (more preferably 8.0% to 10.0%), 1.0% to 1.5% of the lubricant, and 0% to 5% of other excipients, and the sum of the weight percentages of the above components is 100%; or The components and their weight percentages of the pharmaceutical composition are: 10.0% to 16.7% of the active ingredient, 72.7% to 79.3% of the filler, 8.0% to 10.0% of the disintegrant, 1.0% to 1.5% of the lubricant, 1.5% to 2.0% of the glidant, and 0% to 5% of other excipients, and the sum of the weight percentages of the above components is 100%; or The components of the pharmaceutical composition and their weight percentages are: 8.0% to 30.0% of the active ingredient, 60.0% to 80.0% of microcrystalline cellulose, 2.0% to 10.0% of mannitol, 5.0% to 10.0% of one of crospovidone or low-substituted hydroxypropyl cellulose, 0.6% to 2.3% of one or both of sodium stearyl fumarate or polyethylene glycol or magnesium stearate, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%; or The components of the pharmaceutical composition and their weight percentages are: 8.0% to 25.0% of the active ingredient, 60.0% to 78.0% of microcrystalline cellulose, 4.0% to 6.0% of mannitol, 6.0% to 10.0% of one or both of crospovidone or low-substituted hydroxypropyl cellulose, 1.0% to 1.5% of one of sodium stearyl fumarate or polyethylene glycol or magnesium stearate, 1.5% to 2.0% of colloidal silicon dioxide, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%; or The components of the pharmaceutical composition and their weight percentages are: 8.0% to 25.0% of the active ingredient, 60.0% to 78.0% of microcrystalline cellulose, 4.0% to 6.0% of mannitol, 6.0% to 10.0%of one or both of crospovidone or low-substituted hydroxypropyl cellulose, 1.0% to 1.5% of one of sodium stearyl fumarat or polyethylene glycol or magnesium stearate, 1.5% to 2% of colloidal silicon dioxide, and 0% to 5% of other excipients, the sum of the weight percentages of the above components being 100%.

8. A solid oral preparation made from the pharmaceutical composition of any one of claims 1 to 7, preferably a powder, a capsule, a tablet, a granule or a fine granule, more preferably a powder, a capsule or a tablet, more preferably a tablet, more preferably a coated tablet, most preferably a film-coated tablet, wherein the film-coated tablet consists of the pharmaceutical composition of any one of solutions 1 to 7 as a tablet core and a film coating, the film coating adding 1.0% to 10.0%, preferably 2.0% to 5.0%, preferably 2.0% to 4.0% to the weight of the tablet core.

9. A method of preparing a pharmaceutical composition as claimed in any one of claims 1 to 7, comprising: (1) mixing the active ingredient and excipients in a mixing vessel to produce a premix; (2) dry granulation; (3) mixing the prepared granules with excipients to produce the pharmaceutical composition; or (1) preparation: weighing the compound of formula (I) or a pharmaceutically acceptable salt thereof (i.e. the active ingredient) and the corresponding excipients according to the prescription amount; (2) mixing the active ingredient, filler, disintegrant and lubricant in a mixing vessel to produce a premix I, adding the premix I to a tablet granulator for granulation, taking the granulated mixture into a mixing barrel to produce a premix II, and mixing the lubricant in the mixing barrel to produce a premix III; (3) dry granulation; (4) mixing the prepared granules with the excipients except the lubricant in a mixing barrel to produce a total mix I, mixing the lubricant with the total mix I to produce a total mix II, and obtaining the pharmaceutical composition.

10. A process for the preparation of a solid oral formulation as claimed in claim 8, which comprises: The pharmaceutical composition obtained by the preparation method described in claim 9 is packed into a packaging bag by a packaged dose to prepare a powder; or the pharmaceutical composition is filled into a capsule to prepare a capsule; or the pharmaceutical composition is further compressed into a tablet using a suitable tablet press; preferably, the pharmaceutical composition is directly compressed into a tablet using a suitable tablet press; further preferably, the tablet is further prepared into a coated tablet, preferably a film-coated tablet, more preferably a gastric-soluble film-coated tablet.

11. Use of the pharmaceutical composition of any one of claims 1-7 or the solid oral preparation of claim 8 in the preparation of a medicament for preventing and / or treating cardiovascular diseases (CVD); preferably, the cardiovascular diseases (CVD) include but are not limited to atherosclerotic cardiovascular disease (ASCVD), coronary artery stenosis, coronary artery related diseases, aortic valve stenosis, aortic valve stenosis related diseases, heart failure, heart failure related diseases, atrial fibrillation, atrial fibrillation related diseases; the ASCVD includes peripheral vascular disease, peripheral artery related diseases, coronary heart disease, ischemic stroke, ischemic stroke related diseases.